178 related articles for article (PubMed ID: 25318465)
1. A fully synthetic four-component antitumor vaccine consisting of a mucin glycopeptide antigen combined with three different T-helper-cell epitopes.
Palitzsch B; Hartmann S; Stergiou N; Glaffig M; Schmitt E; Kunz H
Angew Chem Int Ed Engl; 2014 Dec; 53(51):14245-9. PubMed ID: 25318465
[TBL] [Abstract][Full Text] [Related]
2. Water-soluble polymers coupled with glycopeptide antigens and T-cell epitopes as potential antitumor vaccines.
Nuhn L; Hartmann S; Palitzsch B; Gerlitzki B; Schmitt E; Zentel R; Kunz H
Angew Chem Int Ed Engl; 2013 Sep; 52(40):10652-6. PubMed ID: 24038824
[TBL] [Abstract][Full Text] [Related]
3. A fully synthetic vaccine consisting of a tumor-associated glycopeptide antigen and a T-cell epitope for the induction of a highly specific humoral immune response.
Dziadek S; Hobel A; Schmitt E; Kunz H
Angew Chem Int Ed Engl; 2005 Nov; 44(46):7630-5. PubMed ID: 16247815
[No Abstract] [Full Text] [Related]
4. Synthesis and immunological evaluation of self-assembling and self-adjuvanting tricomponent glycopeptide cancer-vaccine candidates.
Wilkinson BL; Day S; Chapman R; Perrier S; Apostolopoulos V; Payne RJ
Chemistry; 2012 Dec; 18(51):16540-8. PubMed ID: 23090901
[TBL] [Abstract][Full Text] [Related]
5. MUC1-derived glycopeptide libraries with improved MHC anchors are strong antigens and prime mouse T cells for proliferative responses to lysates of human breast cancer tissue.
Gad M; Jensen T; Gagne R; Komba S; Daugaard S; Kroman N; Meldal M; Werdelin O
Eur J Immunol; 2003 Jun; 33(6):1624-32. PubMed ID: 12778480
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and Immunological Evaluation of a Multicomponent Cancer Vaccine Candidate Containing a Long MUC1 Glycopeptide.
Supekar NT; Lakshminarayanan V; Capicciotti CJ; Sirohiwal A; Madsen CS; Wolfert MA; Cohen PA; Gendler SJ; Boons GJ
Chembiochem; 2018 Jan; 19(2):121-125. PubMed ID: 29120508
[TBL] [Abstract][Full Text] [Related]
7. Self-adjuvanting synthetic antitumor vaccines from MUC1 glycopeptides conjugated to T-cell epitopes from tetanus toxoid.
Cai H; Chen MS; Sun ZY; Zhao YF; Kunz H; Li YM
Angew Chem Int Ed Engl; 2013 Jun; 52(23):6106-10. PubMed ID: 23616304
[TBL] [Abstract][Full Text] [Related]
8. Synthetic multivalent glycopeptide-lipopeptide antitumor vaccines: impact of the cluster effect on the killing of tumor cells.
Cai H; Sun ZY; Chen MS; Zhao YF; Kunz H; Li YM
Angew Chem Int Ed Engl; 2014 Feb; 53(6):1699-703. PubMed ID: 24449389
[TBL] [Abstract][Full Text] [Related]
9. Fully synthetic self-adjuvanting thioether-conjugated glycopeptide-lipopeptide antitumor vaccines for the induction of complement-dependent cytotoxicity against tumor cells.
Cai H; Sun ZY; Huang ZH; Shi L; Zhao YF; Kunz H; Li YM
Chemistry; 2013 Feb; 19(6):1962-70. PubMed ID: 23280874
[TBL] [Abstract][Full Text] [Related]
10. A fully synthetic glycopeptide antitumor vaccine based on multiple antigen presentation on a hyperbranched polymer.
Glaffig M; Palitzsch B; Hartmann S; Schüll C; Nuhn L; Gerlitzki B; Schmitt E; Frey H; Kunz H
Chemistry; 2014 Apr; 20(15):4232-6. PubMed ID: 24623572
[TBL] [Abstract][Full Text] [Related]
11. Microarray Analysis of Antibodies Induced with Synthetic Antitumor Vaccines: Specificity against Diverse Mucin Core Structures.
Pett C; Cai H; Liu J; Palitzsch B; Schorlemer M; Hartmann S; Stergiou N; Lu M; Kunz H; Schmitt E; Westerlind U
Chemistry; 2017 Mar; 23(16):3875-3884. PubMed ID: 27957769
[TBL] [Abstract][Full Text] [Related]
12. Towards a fully synthetic MUC1-based anticancer vaccine: efficient conjugation of glycopeptides with mono-, di-, and tetravalent lipopeptides using click chemistry.
Cai H; Huang ZH; Shi L; Zhao YF; Kunz H; Li YM
Chemistry; 2011 May; 17(23):6396-406. PubMed ID: 21538615
[TBL] [Abstract][Full Text] [Related]
13. Enhanced immunogenicity of multivalent MUC1 glycopeptide antitumour vaccines based on hyperbranched polymers.
Glaffig M; Palitzsch B; Stergiou N; Schüll C; Strassburger D; Schmitt E; Frey H; Kunz H
Org Biomol Chem; 2015 Oct; 13(40):10150-4. PubMed ID: 26299280
[TBL] [Abstract][Full Text] [Related]
14. The development of synthetic antitumour vaccines from mucin glycopeptide antigens.
Gaidzik N; Westerlind U; Kunz H
Chem Soc Rev; 2013 May; 42(10):4421-42. PubMed ID: 23440054
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine.
Ohtake J; Ohkuri T; Togashi Y; Kitamura H; Okuno K; Nishimura T
Immunol Lett; 2014 Sep; 161(1):20-30. PubMed ID: 24794408
[TBL] [Abstract][Full Text] [Related]
16. A synthetic vaccine consisting of a tumor-associated sialyl-T(N)-MUC1 tandem-repeat glycopeptide and tetanus toxoid: induction of a strong and highly selective immune response.
Kaiser A; Gaidzik N; Westerlind U; Kowalczyk D; Hobel A; Schmitt E; Kunz H
Angew Chem Int Ed Engl; 2009; 48(41):7551-5. PubMed ID: 19685547
[No Abstract] [Full Text] [Related]
17. Induction of carbohydrate-specific antibodies in HLA-DR transgenic mice by a synthetic glycopeptide: a potential anti cancer vaccine for human use.
Vichier-Guerre S; Lo-Man R; BenMohamed L; Dériaud E; Kovats S; Leclerc C; Bay S
J Pept Res; 2003 Sep; 62(3):117-24. PubMed ID: 12895273
[TBL] [Abstract][Full Text] [Related]
18. Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine.
Lakshminarayanan V; Thompson P; Wolfert MA; Buskas T; Bradley JM; Pathangey LB; Madsen CS; Cohen PA; Gendler SJ; Boons GJ
Proc Natl Acad Sci U S A; 2012 Jan; 109(1):261-6. PubMed ID: 22171012
[TBL] [Abstract][Full Text] [Related]
19. Synthetic and immunological studies on trimeric MUC1 immunodominant motif antigen-based anti-cancer vaccine candidates.
Li M; Yu F; Yao C; Wang PG; Liu Y; Zhao W
Org Biomol Chem; 2018 Feb; 16(6):993-999. PubMed ID: 29345713
[TBL] [Abstract][Full Text] [Related]
20. Glycopeptide-functionalized gold nanoparticles for antibody induction against the tumor associated mucin-1 glycoprotein.
Cai H; Degliangeli F; Palitzsch B; Gerlitzki B; Kunz H; Schmitt E; Fiammengo R; Westerlind U
Bioorg Med Chem; 2016 Mar; 24(5):1132-5. PubMed ID: 26853835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]